AbsTrACT
Objectives to define the prognostic contribution of global and regional left ventricular (lV) function measurements in patients with ischaemic cardiomyopathy randomised to coronary artery bypass graft surgery (caBg) with (n=501) or without (n=499) surgical ventricular reconstruction (sVr). Methods novel multivariable methods to analyse global and regional lV systolic function were used to better formulate prediction models for long-term mortality following caBg with or without sVr in the entire cohort of 1000 randomised sVr hypothesis patients. Key clinical variables were included in the analysis. regional function was classified according to the discreteness of anteroapical hypokinesia and akinesia into those most likely to benefit from sVr, those least likely and those felt to have intermediate likelihood of benefit from sVr. results the most prognostic clinical variables identified in multivariable models include creatinine, lV endsystolic volume index (esVi), age and nYha (new York heart association) class. addition of lV ejection fraction, lV end-diastolic volume index and regional function assessment did not contribute additional power to the model. subgroup analysis based on regional function did not identify a cohort in which sVr improved mortality. Conclusions esVi is the single parameter of lV function most predictive of mortality in patients with lV systolic dysfunction following caBg with or without sVr in multivariable models that include all key clinical and lV systolic function parameters. assessment of regional cardiac function does not enhance prediction of mortality nor identify a subgroup for which sVr improves mortality. these results do not support elective addition of lV reconstruction surgery in patients undergoing caBg. Trial registration number nct00023595.
InTrOduCTIOn
Surgical treatment is an important part of overall management of patients with left ventricular (LV) dysfunction due to coronary artery disease (CAD). Surgical treatment is most commonly coronary artery bypass graft (CABG) surgery, but in patients with anterior LV dysfunction, surgical ventricular reconstruction (SVR) may be added to CABG to reconstruct a more normal LV size and shape. 1 Observational evidence suggests that surgical reduction of LV size improves cardiac function, improves quality of life [2] [3] [4] and may decrease mortality. The randomised Surgical Treatment for Ischemic Heart Failure (STICH) trial, however, showed that routine addition of SVR to CABG in patients who have anterior regional dysfunction provided no additional benefit in the survival or quality of life over CABG alone. 2 3 Possible reasons for these conflicting findings have been hotly debated, and there remains great interest in determining whether a subset of patients who benefit from SVR can be found.
Indices of global systolic structure and function, such as LV end-systolic volume index (ESVI) and left ventricular ejection fraction (LVEF), are known to provide prognostic information in patients with heart failure due to ischaemic heart disease treated medically 4 or surgically. 5 Whether assessment of regional LV function adds prognostic value beyond that of global dysfunction in such patients is less clear. Some investigators have reported that assessment of regional LV function using a wall motion score index (WMSI) helps identify patients preoperatively who may benefit most from SVR. 6 This observation is confounded, however, by the fact that extensive segmental LV dysfunction and a high WMSI are commonly associated with large LV volumes, and that WMSI provides an overall measure of LV function from the sum of its regional parts, but does not measure regional distribution of LV dysfunction, which may be critical in deciding whether SVR is indicated.
Regional function is often difficult to quantitate accurately in all patients, especially if only one imaging modality is used. Wall motion in areas other than the anterior wall and apex also appears important, as the presence of posterior wall dysfunction may also compromise survival. 7 Whether mapping of function in the anterior and apical ventricular segments which are the target of the SVR can identify patients with greater likelihood of benefit from SVR is unknown. Apart from the STICH trial, no prospectively acquired database of baseline cardiac images has been available Heart failure and cardiomyopathies to identify patients who are proper candidates for SVR. [8] [9] [10] The 1000 patients in the STICH trial eligible for randomisation to CABG with or without SVR, whose global and segmental LV function were well characterised by multiple imaging modalities provide an ideal cohort in which to examine the prognostic utility of global and regional LV function when added to clinical variables predictive of patient survival. Moreover, this 1000-patient cohort, when compared with a 1036-patient cohort entered into the Society of Thoracic Surgeons' National Database during the enrolment interval of STICH, had similar baseline characteristics, thereby confirming the generalisability of the STICH SVR hypothesis conclusions.
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This analysis of the SVR hypothesis 1000-patient cohort seeks to determine (1) which measures of global LV systolic function best predict long-term survival after cardiac surgery; (2) whether characterisation of segmental function adds independent prognostic information to that provided by prognostic clinical and global cardiac function variables and (3) whether baseline parameters of segmental function identify a subgroup of STICH patients for whom the addition of SVR to CABG improves survival.
MeTHOds

Patient population
The STICH SVR hypothesis examined the effect of adding SVR to CABG in patients with ischaemic heart disease suitable for CABG and an LVEF ≤0.35 with significant anteroapical akinesia or dyskinesia for whom adding SVR to CABG would be a reasonable but not required operative treatment. All participants gave written informed consent, the study was approved by the ethics committees responsible for the participating centres, and this investigation conforms to the principles outlined in the Declaration of Helsinki. The main results have been published elsewhere 2 and reported that after a median follow-up of 3.6 years, death occurred in 141 (28%) of the 499 patients randomised to CABG and 138 (28%) of the 501 patients randomised to CABG with SVR (HR, 1.00; CI, 0.79 to 1.26; p=0.98). There were a total of 279 deaths observed in this cohort. Baseline clinical data used in multivariable modelling were complete for 98% of the patients and baseline core lab LV ESVI data were complete for 87%. Imputations for missing data were performed so all study patients are represented in the final model (see online supplementary appendix 1).
Assessment of LV function at time of randomisation
Baseline assessment of global and regional LV function was measured with echocardiogram (ECHO), gated myocardial perfusion single photon emission CT (SPECT) or cardiac magnetic resonance (CMR) by core laboratories blinded to treatment and outcome. All patients had a baseline LVEF from either a core lab image (n=966) or site-reported value on clinical case report forms (n=34). The reasons for incomplete baseline LV function data are depicted in figure 1 . From 866 of the 1000 SVR hypothesis patients, one or more fair to excellent quality ECHO, SPECT or CMR studies were received and processed by the core laboratories providing a baseline ESVI value. Clinical site-reported baseline ESVI values were available on clinical case report forms for 58 additional patients so that values for baseline ESVI were available for 924 of the 1000 SVR hypothesis patients. ESVI was imputed for the remaining 76 patients using the following regression equation, which was based on the observed relationship between LVEF and ESVI in patients in whom ESVI was measured: 182.02 - 
Categorising regional function by suitability for sVr
For 812 of the 1000 patients who had fair or better core laboratory LV images collected at the segment level, the regional LV function was assessed using 1 (normal), 2 (hypokinesia), 3 (akinesia) and 4 (dyskinesia) scores, which were mapped to a standardised 17-segment model. 12 The distribution and frequency of segmental akinesia and dyskinesia are shown in figure 3. Regional function was classified by grouping patients into those who were most SVR-eligible (largest amount of discrete anteroapical akinesia or dyskinesia), those with least eligibility (smallest amount of discrete anteroapical akinesia or dyskinesia) and those with intermediate eligibility (fewer dysfunctional segments and less discrete transition from normal to dysfunctional segments). The amount of discrete anteroapical akinesia or dyskinesia was defined by summing the wall motion scores in segments 8, 13, 14, 15 and 17.
To neutralise the confounding effect of a large heart size with the extensiveness of LV regional dysfunction, regional function was defined within deciles of increasing ESVI. Each decile was divided into thirds (groups of 33, 33 and 34 patients) as ordered from most to least dyskinesia in segments most likely to benefit from adding SVR to CABG (8, 13, 14, 15 and 17) . The 33, 33 and 34 patients from each of the 10 groupings by ESVI were combined into three cohorts, numbered 330, 330 and 340 patients to reflect thirds of patients expected to be the most, intermediate and least likely to receive benefit from adding SVR to CABG based on regional dysfunction criteria. Because at a clinical level patients without adequate regional wall motion assessment cannot be classified as suitable to SVR, they have been classified as the least eligible. Thus the 340 patients in the group labelled as least eligible to SVR included the 188 patients without core laboratory assessment of regional function and 152 patients with the least discrete and smallest area of anteroapical regional dysfunction. With the exception of race, the baseline characteristics of patients with the least anteroapical dysfunction (least eligible) are similar to those with missing regional data (see online supplementary appendix 2). A sensitivity analysis was also performed excluding the patients without regional function data (see online supplementary appendix 3), and the outcomes for those without regional data were also analysed separately.
Optimisation of baseline esVI prognostic power using preliminary multivariable models
A preliminary model composed of baseline clinical characteristics and site-reported LVEF was developed. Subsequently, site-reported LVEF was substituted with various combinations of global and regional function measures to determine which functional measures maximised the contribution to prognosis of all 1000 patients in the context of clinical variables. Because patients had LVEF and ESVI measures from more than one core lab, 13 algorithms that gave priority to different imaging modalities and quality scores were substituted into the clinical model for all-cause death. Different Heart failure and cardiomyopathies combinations of LVEF, ESVI, end-diastolic volume index (EDVI) and SVR eligibility category based on regional function were also tested for their contribution to the model.
resuLTs
Compliance with randomised treatment assignment
Among the 499 patients randomised to CABG, 463 (92.8%) were compliant with the assigned treatment. Among the 501 patients assigned to CABG + SVR, 454 (90.6%) received their assigned operations (table 1). A total of 979 patients received CABG with or without SVR. The reasons for non-compliance with treatment assignment are described in table 1. Table 2 summarises the results of multivariable modelling that began with the identification of prognostic clinical variables, continued with the introduction of multiple LV function variables and concluded with the maximisation of the model prognostic strength by including the single algorithm of ESVI with the highest total model χ² (if more than one ESVI value was available). The final model result showed that the addition of LVEF, EDVI and regional function did not contribute prognostic information above that of baseline ESVI. Increasing blood creatinine over 1.0 mg/ dL conveyed more prognostic information than ESVI. However, ESVI was more prognostic than age, heart failure class, presence of atrial flutter or fibrillation, diabetes, and six other clinical variables.
Multivariable model results
The univariable relationship of all-cause death to baseline ESVI is depicted at 1, 3 and 5 years for the 979 patients who received surgery stratified by the operation received (figure 4). Operative mortality was greatest among patients with the largest ESVI.
Comparison of clinical characteristics of 1000 patients grouped by sVr eligibility
The baseline clinical and LV function characteristics of the three cohorts created to reflect the most, intermediate and least SVR eligibility show no differences in baseline characteristics that would be likely to introduce bias towards a differential outcome from addition of SVR to CABG (table 3) . The strongest variables in the multivariable model were balanced among the three cohorts. EDVI and LVEF were similar among the three groupings, and thus the key difference between the groups was the distribution of regional function on which the SVR eligibility categories were based. Correlations between baseline ESVI measured using the different imaging modalities have been published elsewhere.
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Interaction of esVI with treatment assignment
There was no significant interaction between baseline ESVI and surgery received (p=0.88). Figure 4 shows survival as a function of baseline ESVI at 1, 3 and 5 years of follow-up. All three paired curves share a similar shape, with CABG + SVR having similar early survival in patients with the smallest baseline ESVI, and CABG alone having visually greater early survival in patients with the largest ESVI.
effect of regional function on outcome
Regional cardiac function of patients grouped by the likelihood of benefit from SVR is shown in figure 3 . By definition, the most SVR-eligible 330-patient cohort had a high prevalence of akinesia or dyskinesia confined to the anteroapical segments. The three groups with a range of eligibility for SVR are well matched for ESVI and LVEF (table 3) . Despite confirmation that the data transform created at least one patient grouping with excellent SVR eligibility, no survival advantage for CABG + SVR occurred among even this most SVR-eligible cohort (figure 5).
Overall mortality was not different among the three SVR-eligible groups, between the treatment received nor their interaction (p=0.45). Mortality rates at 4 years were 27.4% in the most SVR-eligible group, 28.9% in the intermediate group and 25.1% in the least-eligible group. The use of regional wall motion to rank patients by eligibility for SVR produced a cohort for which adding SVR to CABG would be expected to reduce mortality. However, in the most SVR-eligible cohort, the HR for CABG + SVR to CABG was 0.84 (0.55, 1.27). Similar results were seen in a sensitivity analysis that excluded patients with missing regional function (see online supplementary data appendix 3). Further, when outcomes were examined in the 188 patients excluded from the sensitivity analysis with missing regional data, 23/84 (27.4%) of those who received SVR died compared with 26/100 (26.0%) who received CABG alone (p=0.68), a finding that was not different from those seen in the other groups. Four did not undergo operation.
dIsCussIOn
Although the prognostic importance of LV aneurysms was known during the 17th century, the impact of surgical intervention has remained controversial in the 21st century. 14 15 Once coronary revascularisation became the primary objective of operations performed for CAD, LV aneurysms judged to pose a haemodynamic threat to patients undergoing CABG during the time of discontinuation of cardiopulmonary bypass were commonly treated with CABG and aneurysmectomy. Thus LV aneurysmectomy and subsequently its Heart failure and cardiomyopathies refinement, SVR, have been used for 50 years, but evidence for prognostic benefits of adding aneurysmectomy to CABG alone has been lacking outside non-randomised observational studies.
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The SVR hypothesis of the STICH study showed that routine addition of SVR to CABG in those with suitable anatomy offered no survival advantage over CABG alone. 2 This analysis of the STICH SVR hypothesis substudy fills in some of the gaps in knowledge in this area.
Using a novel analysis strategy that allows inclusion of mortality data from all randomised patients in the study, this analysis confirms that ESVI, a measure of global LV structure and function, is the most important cardiac determinant of subsequent survival following CABG with or without SVR, even when the prognostic model includes key clinical parameters known to influence outcome. This conclusion supports previous findings of the prognostic power of ESVI following acute myocardial infarction 4 and following CABG in ischaemic cardiomyopathy, 19 20 and extends our understanding by considering ESVI in conjunction with important clinical variables. Novel findings include showing that assessment of regionality of LV dysfunction, grouped by involvement of the anteroapical myocardial segments targeted by the SVR procedure, offers no additional prognostic information over ESVI for death in this patient group, and that consideration of regionality does not identify a subgroup of the STICH cohort who may benefit from the addition of SVR, both findings with practical implications for treatment of patients with ischaemic cardiomyopathy.
regional function and prognosis
The conclusion that regional function assessment does not add prognostic information to global function assessment differs from the conclusion from observational evidence of Klein et al, 6 who studied 101 patients undergoing SVR. They found that WMSI, but not ESVI or EDVI, predicted poor outcome, defined by death or poor functional capacity, at 1 year following SVR, a finding that they attributed to the ability of WMSI to measure regional variability of function and, in particular, function in areas remote to the anteroapical region. In contrast, we found that although ESVI, a global measure, was prognostically important in this type of cohort, assessment of regional function did not add to the prediction of death following surgery. The possible reasons for these differences include the fact that the study of Klein et al was significantly smaller than ours, with lower statistical power, and that WMSI, although often regarded as an index of regional function, in fact, provides a surrogate measure of global function that is simply derived as the sum of regional function in each of the wall segments. Unless a cluster of adjacent segments are identified with a high wall motion score, an elevated WMSI may simply reflect a dilated cardiomyopathy rather than a pattern of anteroapical regionality. For this reason, we grouped patients according to the regional distribution of dysfunction. When a combined end point of death or heart failure hospitalisation was examined, this conclusion was not changed. Even the third of patients with a distribution of regional dysfunction that was characterised as 'most SVR eligible' by experienced SVR surgeons did not identify a group with whom SVR improved survival. Although the number of events was smaller and confidence intervals were broader within the eligibility subgroups based on regional wall motion, the lack of heterogeneity of treatment effect across the groups supports the validity of this conclusion. This STICH analysis is therefore the only study that has been able to examine the impact of regional function on outcomes in CABG with or without SVR in a randomised cohort as part of a multivariable model.
Inclusion of all randomised patients
This secondary observational analysis performed in a 1000-patient randomised cohort also addresses a major concern raised about the conclusions from the primary STICH SVR outcome report 2 ; that is, that sufficient detailed information was not provided to fully characterise global and regional baseline LV function in all 1000 patients, and patients who may have derived benefit from SVR were therefore not identified. In this study, we have used novel methodology to ensure that clinical and imaging data from all randomised subjects were optimally used to fully exploit the value of integrating parameters of LV global and regional structure and function with key clinical variables to predict death at 5 years following cardiac surgical revascularisation with or without LV size reduction by SVR. The novel methodology used removes the confounding effects of the close relationship between global LV enlargement and LVEF when analysing the impact of the extent and severity of regional dysfunction. It also allows outcome data for all 1000 SVR hypothesis patients to be included, removing any bias that may be present due to exclusion of subjects in whom imaging findings are unavailable.
Because an ESVI value was not available on all patients, we used the calculated relationships with the measured value of LVEF to impute the most likely value of ESVI in a fraction of the patients and thereby account for all deaths among the complete 1000-patient cohort. Previous studies examining this question have excluded subjects for whom all the LV structure and function measures were not available. 13 Moreover, prior reports have not accounted for the strong relationship between the extent of regional wall motion abnormalities and systolic function. 6 We believe this analysis overcomes these weaknesses, confirms the importance of ESVI and confirms a neutral treatment effect of the addition of SVR to CABG.
Clinical implications
Hernandez et al reported data from the Society of Thoracic Surgeons database of cardiac operations for 2436 LV aneurysm repairs and identified 731 SVR operations that were performed outside the clinical trial setting during the 2002-2004 interval when the SVR hypothesis was actively enrolling patients. 21 They reported significant morbidity and mortality in relation to the use of the SVR operation in a real-world evaluation. The STICH trial results, including this analysis in which no subgroup who may benefit from SVR operation was found, suggest cardiac surgeons should carefully consider re-evaluation of indications for operations performed solely for the indication to decrease LV size.
Myocardial revascularisation alone appears to provide adequate benefit for most patients undergoing cardiac surgery for CAD.
Limitations
We have not included parameters of diastolic filling and right ventricular function in this report. Our use of the 17-segment Heart failure and cardiomyopathies description of regionality of LV dysfunction, which is a more granular description of regionality than the shape classifications of Di Donato et al, 1 did not show prognostic significance. Moreover, exclusions to STICH trial enrolment of patients presenting in shock, patients with evolving myocardial infarction and patients with aortic valve disease limit the extension of the conclusions to patients with these markers of higher operative risk. Our findings do not evaluate the value of adding SVR or LV aneurysmectomy to CABG in patients with a strong rationale for LV surgery, such as LV injury during median sternotomy, or unusual morbid conditions, such as intracavity thrombus or ventricular septal defects from an ischaemic aetiology. There are also a number of patients with missing data requiring imputation (see online supplementary data appendix 1), although sensitivity analysis suggests the overall conclusions are not altered by this. Finally, the number of patients and event rates are smaller as subgroup analysis is undertaken reducing the power to detect differences in treatment effects between groups.
COnCLusIOns
Using a multivariable modelling approach incorporating imaging data from multiple modalities and allowing all 1000 STICH SVR hypothesis patients to be analysed, we have shown that ESVI remains the best parameter of LV structure and function predicting outcome in patients undergoing CABG when considered in the context of other important clinical variables. Importantly, we have also shown that regional function assessment incorporating the extent and severity of anteroapical akinesia does not contribute significant prognostic information to that of ESVI alone and does not identify a group of patients for whom the elective addition of SVR improves mortality.
Key messages
What is already known on this subject? ► Routine addition of surgical ventricular reconstruction (SVR) to coronary artery bypass graft surgery (CABG) does not reduce mortality in patients with ischaemic cardiomyopathy. ► Although global measures of left ventricular (LV) structure and function such as end-systolic volume index (ESVI) predict survival in surgical and non-surgical patients with LV systolic dysfunction, it is unclear whether regionality of LV dysfunction provides additional prognostic information or identifies a patient subgroup who may benefit from SVR.
What might this study add?
► We have shown that when added to important clinical parameters, ESVI is the strongest measure of global LV structure and function predicting mortality after CABG with or without SVR, and the regional distribution of LV dysfunction does not add further prognostic information nor identify a patient subgroup who may benefit from the addition of SVR to CABG.
How might this impact on clinical practice?
► Accurate quantification of ESVI provides important prognostic information about the likely outcome of patients who undergo surgical treatment of ischaemic cardiomyopathy and should be routinely measured. There does not appear to be a role for routine addition of SVR in patients undergoing CABG and quantification of regionality does not help with this decision. 
